Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19.SB9.CAR-EBVST
- Development stage
- Preclinical
- Lead developer
- Tikva Allocell
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19.SB9.CAR-EBVST is an investigational, preclinical armored allogeneic chimeric antigen receptor (CAR) T-cell therapy built on donor-derived Epstein-Barr virus-specific T cells (EBVSTs). Developed by Tikva Allocell, the therapy is engineered to target CD19, a B-cell antigen, and is armored with SerpinB9 (SB9) to resist granzyme-B-mediated immune rejection and caspase-mediated apoptosis. This design aims to enhance the persistence of the donor T cells and enable a lymphodepletion-free approach for the treatment of autoimmune diseases, specifically systemic lupus erythematosus (SLE).
02
Targets
Beyond the preview
Go deeper on CD19.SB9.CAR-EBVST.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19.SB9.CAR-EBVST.